BioSpace News Archive

M3 Biotechnology is a clinical stage company with a novel platform of disease-modifying regenerative therapies particularly relevant to neurodegenerative diseases, with a focus on Alzheimer’s. M3’s lead asset, NDX-1017, modifies growth factor systems and is advanced as a first-in-class, disease-modifying treatment with the potential to restore lost connections between brain cells, turning degeneration into regeneration.

The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication.

ANGLE plc, a world-leading liquid biopsy company, announces that its AGM will be held at 2:00pm on Tuesday 31 October 2017 at ANGLE plc, 10 Nugent Road, the Surrey Research Park, Guildford, GU2 7AF.

The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

Five Prime will host a conference call and live audio webcast on Monday, November 6, 2017, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company’s financial results and provide a general business update.

At this DC meeting, attendees will view the system’s 60-second non-invasive evaluation of liver stiffness with real-time ShearWave Elastography.

BullFrog AI, Inc. is pleased to announce the launch of its company with the goal to become a key enabler for the biopharma industry.

Participants may access the conference call live via webcast on the Investor Relations section of the INC Research website.

DCPrime BV and apceth Biopharma GmbH, an established contract manufacturing organization in the field of gene and cell therapy, report today that they have entered into a strategic manufacturing agreement.

Biofrontera today provided an update on the commercialization progress for its combination topical prescription drug Ameluz and medical device BF-RhodoLED for the photodynamic therapy (PDT) of actinic keratosis, a skin cancer precursor, in the United States.